


WHAT IS CLAIMED IS:

1. A compound having the Formula IV:



IV

wherein:

R^1 , R^2 , R^3 , R^4 and R^5 independently represent hydrogen, halogen, alkyl, aryl, aralkyl, heteroaryl or heteroarylalkyl;

R^6 , R^7 , R^8 and R^9 independently represent hydrogen, alkyl, hydroxyalkyl, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, carboxyalkyl, aryl or aralkyl;

or R^6 and R^7 are taken together to form $-(CH_2)_p-$, where p is 2-8, while R^8 and R^9 are defined as above; or R^8 and R^9 are taken together to form $-(CH_2)_q-$, where q is 2-8, while R^6 and R^7 are defined as above; or R^6 and R^8 are taken together to form $-(CH_2)_r-$, while r is zero (a bond), 1 or 2, while R^7 and R^9 are defined as above;

X represents oxygen, sulfur, $-CH_2-$, $-NH-$, $-(C=O)NH-$ or $-NH(C=O)-$;

n is from 0 to 4;

m is from 0 to 4;


a is 0 or 1;

D represents oxygen;

v is 0 or 1;

R^{10} , R^{11} , R^{12} and R^{13} independently represent: hydrogen; hydroxy; alkyl; alkoxy; cycloalkyl; aryl, optionally substituted with one or more of halogen, hydroxy, cyano, alkyl, aryl, alkoxy, haloalkyl, arylalkyl, arylalkoxy,

aryloxy, alkylsulfonyl, alkylsulfinyl, alkylalkoxyaryl, monoalkylamino, dialkylamino, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkanoyl; monoalkylamino; dialkylamino; aminoalkyl; monoalkylaminoalkyl; dialkylaminoalkyl; alkanoyl; heteroaryl having 5-14 ring members, optionally substituted with one or more of halogen, hydroxy, cyano, alkyl, aryl, alkoxy, haloalkyl, arylalkyl, arylalkoxy, aryloxy, alkylsulfonyl, alkylsulfinyl, alkylalkoxyaryl, monoalkylamino, dialkylamino, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkanoyl; or



wherein R¹⁷ and R¹⁸ together form -CH₂CH₂-O-, -O-CH₂CH₂-, -O-CH₂-O- or -O-CH₂CH₂-O-; or

R¹⁰ and R¹² are taken together to form -(CH₂)_s-, wherein s is 0 (a bond) or 1 to 4, while R¹¹ and R¹³ are as defined as above; or R¹⁰ and R¹² are taken together to form a double bond when i is 0 and k is 1, while R¹¹ and R¹³ are as defined above; or R¹⁰ and R¹¹ are taken together to form -(CH₂)_t-, wherein t is 2 to 8, while R¹² and R¹³ are as defined as above, or R¹² and R¹³ are taken together to form -(CH₂)_u- wherein u is 2 to 8, while R¹⁰ and R¹¹ are as defined as above;


i is from 0 to 4;

j is from 0 to 4;

k is 0 or 1;

R¹⁴ is hydrogen or a functionality that acts as a prodrug (*i.e.*, converts to the active species by an endogenous biological process such as an esterase, lipase, or other hydrolase), such as alkyl, aryl, aralkyl, dialkylaminoalkyl, 1-morpholinoalkyl, 1-piperidinylalkyl, pyridinylalkyl, alkoxy(alkoxy)alkoxyalkyl, or (alkoxycarbonyl)oxyethyl;

W is:



wherein:

Y is -N- or -CH-;

Z is -N- or -CH-;

R^{15} is hydrogen, halogen, alkyl, aryl or arylalkyl;

R^{16} is hydrogen, alkyl, haloalkyl or halogen;


R^{19} and R^{20} are independently hydrogen, halogen or alkyl;

R^{27} , R^{28} , R^{29} , R^{30} and R^{31} are independently hydrogen, halogen, alkyl, alkoxy or aryl; and

o and p are independently 0, 1 or 2.

2. The compound of claim 1, wherein R^{14} is a prodrug, selected from the group consisting of: alkyl, aryl, aralkyl, dialkylaminoalkyl, 1-morpholinoalkyl, 1-piperidinylalkyl, pyridinylalkyl, alkoxy(alkoxy)alkoxyalkyl, or (alkoxycarbonyl)oxyethyl.

₈)alkylsulfonyl, (C₁₋₈)alkylsulfinyl, (C₁₋₈)alkoxy(C₆₋₁₀)aryl(C₁₋₈)alkyl, mono(C₁₋₈)alkylamino, di(C₁₋₈)alkylamino, amino(C₁₋₈)alkyl, mono(C₁₋₈)alkylamino(C₁₋₈)alkyl, di(C₁₋₈)alkylamino(C₁₋₈)alkyl, (C₁₋₈)alkanoyl; or



wherein R¹⁷ and R¹⁸ together form -CH₂CH₂-O-, -O-CH₂CH₂-, -O-CH₂-O- or -O-CH₂CH₂-O-; or

R¹⁰ and R¹² are taken together to form -(CH₂)_s-, wherein s is 0 (a bond) or 1 to 4, while R¹¹ and R¹³ are as defined as above; or R¹⁰ and R¹² are taken together to form a double bond when i is 0 and k is 1, while R¹¹ and R¹³ are as defined above; or R¹⁰ and R¹¹ are taken together to form -(CH₂)_t-, wherein t is 2 to 8, while R¹² and R¹³ are as defined as above, or R¹² and R¹³ are taken together to form -(CH₂)_u- wherein u is 2 to 8, while R¹⁰ and R¹¹ are as defined as above; or


i is from 0 to 4;


j is from 0 to 4; and

k is 0 or 1;

R¹⁴ is hydrogen or a functionality that acts as a prodrug;

W is:





wherein:

Y is -N- or -CH-;

Z is -N- or -CH-;

R¹⁵ is hydrogen, halogen, (C₁₋₈)alkyl, (C₆₋₁₀)aryl or (C₆₋₁₀)aryl(C₁₋₈)alkyl;

R¹⁶ is hydrogen, (C₁₋₈)alkyl, halo(C₁₋₈)alkyl or halogen;

R¹⁹ and R²⁰ are independently hydrogen, halogen or (C₁₋₈)alkyl; and

R²⁷, R²⁸, R²⁹, R³⁰ and R³¹ are independently hydrogen, halogen, (C₁₋₈)alkyl, (C₁₋₈)alkoxy, or (C₆₋₁₀)aryl and

o and p are independently 0, 1 or 2.

4. The compound of claim 1, wherein R¹ and R² independently represent hydrogen, halogen, (C₁₋₆)alkyl, (C₆₋₁₀)aryl, (C₆₋₁₀)ar(C₁₋₆)alkyl, 5-14 member heteroaryl, or 5-14 member heteroaryl(C₁₋₈)alkyl.

5. The compound of claim 4, wherein R¹ and R² independently represent hydrogen, methyl, ethyl, propyl, butyl, phenyl, benzyl or phenylethyl.

6. The compound of claim 5, wherein R¹ and R² independently represent hydrogen, methyl, ethyl or propyl.

7. The compound of claim 1, wherein R^3 , R^4 and R^5 independently represent hydrogen, (C_{1-6}) alkyl, (C_{6-10}) aryl, or (C_{6-10}) ar (C_{1-6}) alkyl.










8. The compound of claim 7, wherein R^3 , R^4 and R^5 are hydrogen or (C_{1-4}) alkyl.

9. The compound of claim 1, wherein R^6 , R^7 , R^8 and R^9 independently represent hydrogen, halogen or (C_{1-6}) alkyl.

10. The compound of claim 1, wherein X is oxygen, $-CH_2-$ or $-(C=O)NH-$.

11. The compound of claim 10, wherein X is oxygen or $-CH_2-$.

12. The compound of claim 1, wherein W is:



wherein:

Y is -N- or -CH-;


R^{15} is hydrogen, halogen, (C_{1-8}) alkyl, (C_{6-10}) aryl or (C_{6-10}) aryl (C_{1-8}) alkyl;

R^{16} is hydrogen, (C_{1-8}) alkyl, halo (C_{1-8}) alkyl or halogen;

R^{19} and R^{20} are hydrogen, halogen or (C_{1-8}) alkyl; and

R^{27} , R^{28} , R^{29} , R^{30} and R^{31} are hydrogen, halogen, (C_{1-8}) alkyl, (C_{1-8}) alkoxy, or (C_{6-10}) aryl.

13. The compound of claim 1, wherein W is



wherein:


R^{15} is hydrogen, halogen, (C_{1-8}) alkyl, (C_{6-10}) aryl or (C_{6-10}) aryl (C_{1-8}) alkyl;

R^{16} is hydrogen, (C_{1-8}) alkyl, halo (C_{1-8}) alkyl or halogen;

R^{19} and R^{20} are hydrogen, halogen or (C_{1-8}) alkyl; and


R^{27} , R^{28} , R^{29} , R^{30} and R^{31} are hydrogen, halogen, (C_{1-8}) alkyl, (C_{1-8}) alkoxy, or (C_{6-10}) aryl.

14. The compound of claim 13, wherein W is




15. The compound of claim 1, wherein R^{10} , R^{11} , R^{12} and R^{13} independently represent: hydrogen; hydroxy, (C_{1-12}) alkyl; (C_{3-6}) cycloalkyl; or (C_{6-10}) aryl, optionally substituted with one or more of halogen, hydroxy, cyano, (C_{1-8}) alkyl, (C_{6-10}) aryl, (C_{1-8}) alkoxy, halo (C_{1-8}) alkyl, (C_{6-10}) aryl (C_{1-8}) alkyl, (C_{6-10}) aryl (C_{1-8}) alkoxy, or (C_{6-10}) aryloxy.

16. The compound of claim 1, wherein R^{10} , R^{11} , R^{12} and R^{13} independently represent a heteroaryl having 5-14 ring members, optionally substituted with one or more of halogen, hydroxy, cyano, (C_{1-8}) alkyl, (C_{1-8}) alkoxy (C_{6-10}) aryl, (C_{1-8}) alkoxy, halo (C_{1-8}) alkyl, (C_{6-10}) aryl (C_{1-8}) alkyl, (C_{6-10}) aryl (C_{1-8}) alkoxy, (C_{6-10}) aryloxy, (C_{1-8}) alkylsulfonyl, (C_{1-8}) alkylsulfinyl, (C_{1-8}) alkylamino, (C_{1-8}) alkylamino (C_{1-8}) alkyl, di (C_{1-8}) alkylamino, di (C_{1-8}) alkylamino (C_{1-8}) alkyl, or carboxy (C_{1-8}) alkyl; or



wherein R^{17} and R^{18} together form $-\text{CH}_2\text{CH}_2-\text{O}-$, $-\text{O}-\text{CH}_2\text{CH}_2-$, $-\text{O}-\text{CH}_2-\text{O}-$ or $-\text{O}-\text{CH}_2\text{CH}_2-\text{O}-$.

17. The compound of claim 1, wherein R^{12} and R^{13} are independently thiazolyl, benzofuranyl,



wherein:

b is from 0 to 4;

R^{32} is halogen, (C_{1-6}) alkyl, halo (C_{1-6}) alkyl, (C_{1-6}) alkoxy, (C_{1-6}) alkoxy (C_{1-6}) alkyl or halo (C_{1-6}) alkoxy;

R³³ is halogen; and

R³⁴ is (C₁₋₆)alkyl, hydroxy or (C₁₋₆)alkoxy, or

two of R³², or two of R³³, or one of R³³ and R³⁴, when attached to adjacent carbon atoms, may together form a ring, wherein the ring formed is an aliphatic, aryl or heteroaryl ring, each of which may be optionally substituted by one or more of halogen, hydroxy, cyano, alkyl, aryl, alkoxy, haloalkyl, arylalkyl, arylalkoxy, aryloxy, alkylsulfonyl, alkylsulfinyl, alkoxyarylalkyl, monoalkylamino, dialkylamino, aminoalkyl, monoalkylaminoalkyl, dialkylaminoalkyl, alkanoyl; monoalkylamino; dialkylamino; aminoalkyl; monoalkylaminoalkyl; dialkylaminoalkyl; alkanoyl.

18. The compound of claim 1, wherein R¹⁰ and R¹² are taken together to form a double bond where i is 0 and k is 1, and R¹¹ and R¹³ are each hydrogen.

19. The compound of claim 1, wherein R¹⁰ is an optionally substituted aryl or an optionally substituted heteroaryl.

20. The compound of claim 1, wherein i and j are each 0.

21. The compound of claim 1, wherein k is 1.

22. The compound of claim 1, wherein R¹⁴ is hydrogen.

23. The compound of claim 1, wherein i and j are each zero; k is one; R¹⁰, R¹¹ and R¹² are each hydrogen; and R¹³ is hydrogen, (C₁₋₆)alkyl, (C₆₋₁₀)aryl or (C₆₋₁₀)ar(C₁₋₄)alkyl.

24. The compound of claim 1, wherein:

R¹ is hydrogen or (C₁₋₄)alkyl;

R^2, R^3, R^4 , and R^5 are hydrogen or (C_{1-4}) alkyl;

R^6, R^7, R^8 and R^9 are hydrogen or (C_{1-4}) alkyl;

X is oxygen or $-CH_2-$;

n is 0 or 1;

m is 0 or 1;

R^{10}, R^{11}, R^{12} and R^{13} independently represent hydrogen, (C_{1-6}) alkyl or (C_{6-10}) aryl (C_{1-6}) alkyl; or

one of the combination R^{10} and R^{11} , R^{12} and R^{13} or R^{10} and R^{12} are taken together to form $-(CH_2)_s-$, wherein s is 1 or 2 while the remaining of R^{10} - R^{13} are as defined above;








i is 0 or 1;

j is 0 or 1;


k is 0 or 1;

R^{14} is hydrogen, C_{1-6} alkyl or benzyl;

W is:



OR



wherein:

Y is $-N-$ or $-CH-$;

R^{15} is hydrogen, halogen, (C_{1-8}) alkyl, (C_{6-10}) aryl or (C_{6-10}) aryl (C_{1-8}) alkyl;

R^{16} is hydrogen, (C_{1-8}) alkyl, halo (C_{1-8}) alkyl or halogen;

R^{19} and R^{20} are hydrogen, halogen or (C_{1-8}) alkyl; and

R^{27} , R^{28} , R^{29} , R^{30} and R^{31} are hydrogen, halogen, (C_{1-8}) alkyl, (C_{1-8}) alkoxy, or (C_{6-10}) aryl.

25. The compound of claim 24, wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{11} , R^{12} , R^{13} and R^{14} are hydrogen.

26. The compound of claim 1, wherein R^{10} and R^{11} are taken together to form $-(CH_2)_t-$, where t is 2 to 5 and R^{12} and R^{13} are each hydrogen.

27. The compound of claim 1, wherein R^{12} and R^{13} are taken together to form $-(CH_2)_u-$, where u is 2 to 5 and R^{10} and R^{11} are each hydrogen.

28. The compound of claim 1, wherein R^{10} and R^{12} are taken together to form $-(CH_2)_s-$ where s is zero or 1 to 4, and R^{11} and R^{13} are each hydrogen.

29. The compound of claim 1, wherein:

X is $-(C=O)NH-$;

n, m, a and v are each 0; and

R^6 , R^7 , R^{12} and R^{13} are hydrogen.

30. The compound of claim 1, wherein:

X is oxygen;

n and m are each 0;

a and v are each 1;

D is oxygen;

R^6 , R^7 , R^8 and R^9 are hydrogen.

31. The compound of claim 1, wherein:

X is oxygen;

n, m and v are each 0;

a is 1; and

R⁶, R⁷, R¹² and R¹³ are hydrogen.

32. The compound of claim 1, wherein:

X is -CH₂-;

n, m and v are each 0;

a is 1; and

R⁶, R⁷, R¹² and R¹³ are hydrogen.

33. The compound of claim 1, wherein v is 0.

34. The compound of claim 1, wherein

R¹ is hydrogen or -CH₃;

R², R³, R⁴, R⁵, R⁶, R⁷, R⁸ and R⁹ are hydrogen;

X is oxygen or -CH₂-;

n is 0 or 1;

m is 0 or 1;

R¹⁰, R¹¹, R¹² and R¹³ independently represent hydrogen,

(C₁-C₆)alkyl or (C₆₋₁₀)ar(C₁₋₆)alkyl; or

one of the combination R¹⁰ and R¹¹, R¹² and R¹³ or R¹⁰ and R¹²

are taken together to form -(CH₂)_s-, wherein s is 1 while the remaining of R¹⁰-R¹³ are defined above;


i is 0 or 1;

j is 0 or 1;

k is 0 or 1;

R¹⁴ is hydrogen or alkyl;

W is:



wherein:

R^{15} is hydrogen, halogen, (C_{1-8}) alkyl, (C_{6-10}) aryl or (C_{6-10}) aryl (C_{1-8}) alkyl;

R^{16} is hydrogen, (C_{1-8}) alkyl, halo (C_{1-8}) alkyl or halogen;

R^{27} , R^{28} , R^{29} , R^{30} and R^{31} are hydrogen, halogen, (C_{1-8}) alkyl, (C_{1-8}) alkoxy, or (C_{6-10}) aryl.

35. The compound of claim 1, wherein:

v , m , n , i and j are 0;

a is 1;

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{11} , R^{12} , R^{13} and R^{14} are each hydrogen; and

R^{10} is pyridinyl.

36. The compound of claim 1, wherein:

v , m , n , i and j are 0;

a is 1;

R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{11} , R^{12} , R^{13} and R^{14} are each hydrogen; and

R^{10} is quinolinyl.

37. The compound of claim 1, wherein:

v , m , n , i and j are 0;

R¹, R², R³, R⁴, R⁵, R⁶, R⁷, R⁸, R⁹, R¹¹, R¹², R¹³ and R¹⁴ are each hydrogen; and
R¹⁰ is methoxyphenyl.

hydrogen; and

R¹⁰ is methoxyphenyl.

acid;

3-{5-[3-(2-pyridylamino)propoxy]indolyl}propanoic acid;

3-{5-[3-(2-pyridylamino)propoxy]indolyl}acetic acid;

3-{2-methyl-5-[3-(2-pyridylamino)propoxy]indolyl}propanoic acid;

2-(trans-2-{5-[3-(2-pyridylamino)propoxy]indolyl} cyclopropyl)acetic

3-(5-{2-[6-(methylamino)-2-pyridyl]ethoxy}indolyl)propanoic acid;

2-benzyl-3-{5[3-(2-pyridylamino)propoxy]indolyl}propanoic acid;

2-methyl-3-{5-[3-(2-pyridylamino)propoxy]indolyl}propanoic acid;

2-({5-[3-(2-pyridylamino)propoxy]indolyl}methyl)pentanoic acid;

2-({5-[3-(2-pyridylamino)propoxy]indolyl}methyl)octanoic acid;

3-[5-(3-{[benzylamino]carbonylamino}propoxy)indolyl] propanoic

acid;

3-[5-(2-5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl-acetylamino)-indol-1-yl]-hexanoic acid;

3-(5-{2-[N-(4,5-dihydro-1H-imidazol-2-yl)-aminoxy]-ethoxy}-indol-1-yl)-3-phenyl-propionic acid;

3-(5-{2-[guanidino-oxy]-ethoxy}-indol-1-yl)-3-phenyl-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-hexanoic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-phenyl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-phenyl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3-benzyloxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-p-tolyl-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-m-tolyl-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-o-tolyl-propionic acid;

3-biphenyl-4-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3,5-dichloro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3,5-difluoro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3-cyano-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(4-cyano-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(2-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(4-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-quinolin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(3-chloro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-naphthalen-2-yl-3-{5-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(2-chloro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-naphthalen-1-yl-3-{5-[2-(5,6,7,8-Tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(4-fluoro-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-(3-trifluoromethyl-phenyl)-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-(4-trifluoromethyl-phenyl)-propionic acid;

3-pyridin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-2-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-4-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-acrylic acid;

3-(2,3-dihydro-benzofuran-5-yl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-benzo[1,3]dioxol-5-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-(5-methanesulfonyl-pyridin-3-yl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-{5-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-indol-1-yl}-3-phenyl-propionic acid;

3-{5-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-indol-1-yl}-3-quinolin-3-yl-propionic acid;

3-{5-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-indol-1-yl}-3-pyridin-3-yl-propionic acid;

3-{5-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-indol-1-yl}-hexanoic acid;

3-{5-[2-(2-methyl-5,6,7,8-tetrahydro-[1,8]naphthyridin-3-yl)-ethyl]-indol-1-yl}-propionic acid;

3-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-indol-1-yl}-propionic acid;

3-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-indol-1-yl}-hexanoic acid;

3-phenyl-3-{5-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-propyl]-indol-1-yl}-propionic acid;

3-{5-[2-(3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-6-yl)-ethoxy]-indol-1-yl}-3-phenyl-propionic acid;

3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-3-[5-(2,2,2-trifluoro-ethoxy)-pyridin-3-yl]-propionic acid;

3-(5-ethoxy-pyridin-3-yl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-4-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-2-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-acrylic acid;

6-(2-hydroxy-ethyl)-2,3-dihydro-pyrido[3,2-b][1,4]oxazine-4-carboxylic acid tert-butyl ester;

3-{5-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-indol-1-yl}-3-quinolin-3-yl-propionic acid;

or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.

39. The compound of claim 1, which is one of:

3-(3-methoxy-phenyl)-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-quinolin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-3-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-pyridin-2-yl-3-{5-[2-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl)-ethoxy]-indol-1-yl}-propionic acid;

3-{5-[2-(6-methylamino-pyridin-2-yl)-ethoxy]-indol-1-yl}-3-quinolin-3-yl-propionic acid;
or a pharmaceutically acceptable salt, hydrate, solvate or prodrug thereof.

40. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable carrier or diluent.

41. A method of treating a pathological condition selected from the group consisting of tumor growth, metastasis, osteoporosis, restenosis, inflammation, macular degeneration, diabetic retinopathy, rheumatoid arthritis and sickle cell anemia, in a mammal in need of such treatment, comprising administering to said mammal an effective amount of a compound of claim 1.

42. The method of claim 41, wherein said condition is tumor growth.

43. The method of claim 41, wherein said condition is osteoporosis.

44. The method of claim 41, wherein said condition is restenosis.

45. The method of claim 41, wherein said condition is inflammation.

46. The method of claim 41, wherein said condition is macular degeneration.


47. The method of claim 41, wherein said condition is diabetic retinopathy.

48. The method of claim 41, wherein said condition is rheumatoid arthritis.

49. The method of claim 41, wherein said condition is sickle cell anemia.


50. A process for preparing a substituted indole compound of claim 1, comprising:

reacting a compound of Formula V:



or a salt, hydrate or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , i and j are as defined in claim 1,


with the compound of Formula VI or Formula X:



or a salt, hydrate or solvate thereof, wherein R^{15} , R^{16} , R^{27} , R^{28} and R^{29} are as defined in claim 1, to form a substituted indole compound of claim 1.

51. A process for preparing a substituted indole compound of claim 1, comprising:


reacting a compound of Formula V:



V

or a salt, hydrate or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , i and j are as defined in claim 1,

with the compound of Formula IX:




IX

or a salt, hydrate or solvate thereof, wherein R^{16} , R^{19} and R^{20} are as defined in claim 1, and R^{35} is alkyl, aryl, alkylaryl or arylalkyl, followed by removal of the R^{35} containing protecting group, to form a substituted indole compound of claim 1.

52. A process for preparing a substituted indole compound of claim 1, comprising:


reacting a compound of Formula V:



V

or a salt, hydrate or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , i and j are as defined in claim 1,

with the compound of Formula VII:




VII

or a salt, hydrate or solvate thereof, wherein R^6 , R^7 , R^8 , R^9 , R^{16} , m and n are as defined in claim 1, to form a substituted indole compound of claim 1.

53. A process for preparing a substituted indole compound of claim 1, comprising:

reacting a compound of Formula VIII:



VIII

or a salt, hydrate or solvate thereof, wherein R^1 , R^2 , R^3 , R^4 , R^5 , R^6 , R^7 , R^8 , R^9 , R^{10} , R^{11} , R^{12} , R^{13} , R^{14} , i, j, k, m and n are as defined in claim 1, with $R^{15}NCO$, where R^{15} is as defined in claim 1, to form a substituted indole compound of claim 1.

54. A method for treating a central nervous system (CNS) related disorder, selected from the group consisting of: neuronal loss associated with stroke, ischemia, CNS trauma, hypoglycemia, surgery, a neurodegenerative disease, an adverse consequence of overstimulation of one or more excitatory amino acids, schizophrenia, anxiety, convulsions, chronic pain, psychosis, anesthesia, and opiate tolerance, in a mammal in need of such treatment, comprising administering to said mammal an effective amount of a compound of claim 1.

55. The method according to claim 54, wherein said CNS related disorder is neuronal loss associated with stroke.

56. The method according to claim 54, wherein said CNS related disorder is ischemia.

57. The method according to claim 54, wherein said CNS related disorder is CNS trauma.

58. The method according to claim 54, wherein said CNS related disorder is hypoglycemia.

59. The method according to claim 54, wherein said CNS related disorder is the result of surgery.

60. The method according to claim 54, wherein said CNS related disorder is a neurodegenerative disease.


61. The method according to claim 60, wherein said neurodegenerative disease is selected from Alzheimer's disease or Parkinson's disease.

62. The method according to claim 54, wherein said CNS related disorder is schizophrenia.

63. The method according to claim 41, wherein the activity of $\alpha 4$ integrin is inhibited.

64. The method according to claim 54, wherein the activity of $\alpha 4$ integrin is inhibited.

65. The compound according to claim 17, wherein R^{12} and R^{13} are independently selected from:



or

